<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Disease Progression Modeling | Robel Gebre</title><link>https://iborz.org/tags/disease-progression-modeling/</link><atom:link href="https://iborz.org/tags/disease-progression-modeling/index.xml" rel="self" type="application/rss+xml"/><description>Disease Progression Modeling</description><generator>HugoBlox Kit (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Thu, 18 Jun 2026 00:00:00 +0000</lastBuildDate><image><url>https://iborz.org/media/logo.svg</url><title>Disease Progression Modeling</title><link>https://iborz.org/tags/disease-progression-modeling/</link></image><item><title>TPE: finding the turning point in disease progression</title><link>https://iborz.org/blog/tpe/</link><pubDate>Thu, 18 Jun 2026 00:00:00 +0000</pubDate><guid>https://iborz.org/blog/tpe/</guid><description>&lt;p&gt;A disease does not progress in a straight line. It drifts, then turns, and the turn is the part that matters.&lt;/p&gt;
&lt;p&gt;A biomarker can changes gradually until it passes a critical point and then accelerates. The trajectory bends, and from one patient to the next that bend lands in a different place, pushed around by age, genetics, and everything else that makes a person who they are. Average the curves together and the turn smears into nothing.&lt;/p&gt;
&lt;p&gt;I built the transition point estimator (TPE) to find that turn directly. It uses machine learning to model the nonlinear link between a biomarker and an outcome, keeps the confounders in check, and reads off the point where each marker&amp;rsquo;s behavior shifts. That point becomes its cutpoint.&lt;/p&gt;
&lt;p&gt;A cutpoint set this way is important in how the disease actually moves. Find the turn, and you find the moment worth acting on.&lt;/p&gt;</description></item></channel></rss>